热门资讯> 正文
ARS Pharma获得2.5亿美元贷款以加速Neffy的推出
2025-09-30 04:19
- ARS Pharmaceuticals (NASDAQ:SPRY) announced a $250M senior secured term loan with affiliates of RA Capital and OMERS Life Sciences.
- An initial $100M draw will support the commercial expansion of neffy, its needle-free epinephrine nasal spray.
- Funds will also back marketing and medical efforts to build real-world evidence of neffy's effectiveness, aligning it with traditional epinephrine injections.
- Source: Press release
More on ARS Pharmaceuticals
- ARS Pharmaceuticals: A Significant Upside Is Expected From neffy
- ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
- ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine
- ARS Pharma rises after Japan nod for neffy nasal spray for allergy
- ARS Pharma drops 9% as Lupin files application for generic neffy
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
